論文業績

  1. Maeda S, Sato T, Nishiofuku H, Toyoda S, Taiji R, Matsumoto T, Chanoki Y, Tachiiri T, Kunichika H, Sho M, Tanaka T.
    Intra-arterial Therapy Using Micellar Nanoparticles Incorporating SN-38 in a Rat Pancreatic Tumor Model.
    Cardiovasc Intervent Radiol. 2025 Mar;48(3):372-378
  2. Nakahara H, Doi S, Yasuda S, Nagai M, Nakamura K, Matsuo Y, Terai T, Kohara Y, Sakata T, Sho M.
    Small bowel perforation caused by a fish bone in a patient with vascular Ehlers-Danlos syndrome: a case report.
    J Surg Case Rep. 2025 Feb 28;2025(2):rjaf098
  3. Miyakita H, Yamamoto S, Uchino M, Hiroki I, Okabayashi K, Shiro O, Futami K, Itabashi M, Watanabe K, Shibutani M, Okita Y, Wakai T, Mizuuchi Y, Okamoto K, Yamada K, Sato Y, Ogino T, Kimura H, Takahashi K, Hida K, Kinugasa Y, Ishida F, Okuda J, Daito K, Yamamoto T, Koyama F, Hanai T, Komori K, Shida D, Noguchi T, Sugihara K, Ajioka Y, Ishihara S; Study Group for Inflammatory Bowel Disease Associated Intestinal Cancers by the Japanese Society for Cancer of the Colon and Rectum.
    Clinical features by disease duration in ulcerative colitis-associated cancers.
    Colorectal Dis. 2025 Mar;27(3):e70044.
  4. Kagami S, Funahashi K, Kobayashi H, Kotake K, Kawasaki M, Kinugasa Y, Ueno H, Maeda K, Suto T, Itabashi M, Ozawa H, Koyama F, Noura S, Ishida H, Ohue M, Kiyomatsu T, Ishihara S, Koda K, Baba H, Kawada K, Hashiguchi Y, Goi T, Toiyama Y, Tomita N, Sunami E, Fujita F, Watanabe J, Hakamada K, Nakayama G, Sugihara K, Ajioka Y.
    Factors Affecting the Prognosis after Primary Tumor Resection for Patients with Metastatic Colorectal Cancer with Synchronous Peritoneal Metastasis: A Multi-center, Prospective, Observational Study.
    J Anus Rectum Colon. 2025 Jan 25;9(1):134-144.
  5. Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group（including Koyama.F）.
    Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
    Lancet. 2025 Jan 4;405(10472):33-49.